Genmab — Oktober 2016
-
Første linie godkendelse, gode dara subcut data på ASH, forlænget Pollux PFS på ASH, måske lidt tisotumab og duobody data på kapitalmarkedsdagen. Det bliver helt sikkert godt

-
- Information om daraus immunmodulerende effekt ligeledes på ASH. Der er så meget godt i vente Pauly. Og alt er ikke priset ind!
-
"daras"
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind